Article
Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
Diabetes - 1 Sept 1998
Penno G, Chaturvedi N, Talmud P J, Cotroneo P, Manto A, Nannipieri M, Luong L A, Fuller J H
Abstract excerpt
We examined whether the ACE gene insertion/deletion (I/D) polymorphism modulates renal disease progression in IDDM and how ACE inhibitors influence this relationship. The EURODIAB Controlled Trial of Lisinopril in IDDM is a multicenter randomized placebo-controlled trial in 530 nonhypertensive, m...
Topics
- Adult
- Albuminuria
- Angiotensin-Converting Enzyme Inhibitors
- Blood Pressure
- Diabetes Mellitus, Type 1
- Diabetic Nephropathies
- Disease Progression
- Follow-Up Studies
- Genotype
- Humans
- Lisinopril
- Middle Aged
- Peptidyl-Dipeptidase A